On June 2, 2025, Chosa Oncology AB's Board of Directors resolved on a strategic financial maneuver involving a directed issue of shares and warrants series TO 2, alongside a rights issue of units, collectively aimed at raising approximately SEK 19.9 million. The Rights Issue has now concluded, with a total subscription rate of 9.46%, resulting in an initial capital influx of SEK 1.6 million for Chosa before issue-related expenses.

The Rights Issue, which consisted of 525,507 units subscribed by exercise of unit rights and 313,179 units without unit rights, reflects a moderate interest from investors. Each unit comprises three shares and three warrants series TO 2, with the potential for further capital injection in July 2026 upon the exercise of these warrants.

Chosa Oncology plans to utilize the funds to further its business plan, focusing on achieving key milestones in the coming months. The company anticipates that the raised capital will sustain its operations through the first quarter of 2026, although it will continuously evaluate its financial needs as it progresses.

For investors, the current situation presents a nuanced decision-making landscape. The partial subscription indicates a cautious market sentiment, yet the strategic direction of Chosa Oncology, underpinned by its focus on oncology and biotechnology, holds promise. The potential for additional capital through the exercise of warrants in 2026 adds a layer of future financial security.

Given these dynamics, investors may consider a 'hold' strategy. While the immediate subscription results are modest, the company's long-term prospects in the oncology sector, alongside its strategic partnerships and innovative pipeline, suggest potential for growth. Investors should remain vigilant, monitoring upcoming milestones and market conditions that could impact Chosa's valuation.